Elevation Point Wealth Partners LLC Has $904,000 Stock Position in Becton, Dickinson and Company (NYSE:BDX)

Elevation Point Wealth Partners LLC boosted its stake in Becton, Dickinson and Company (NYSE:BDX) by 30.0% during the first quarter, according to the company in its most recent filing with the SEC. The fund owned 3,947 shares of the medical instruments supplier’s stock after buying an additional 911 shares during the period. Elevation Point Wealth Partners LLC’s holdings in Becton, Dickinson and Company were worth $904,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also bought and sold shares of BDX. Brighton Jones LLC grew its stake in Becton, Dickinson and Company by 98.2% in the 4th quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock valued at $401,000 after buying an additional 877 shares during the last quarter. Empowered Funds LLC raised its position in shares of Becton, Dickinson and Company by 12.9% in the fourth quarter. Empowered Funds LLC now owns 6,623 shares of the medical instruments supplier’s stock valued at $1,503,000 after buying an additional 756 shares in the last quarter. Allspring Global Investments Holdings LLC raised its position in shares of Becton, Dickinson and Company by 56.5% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 45,792 shares of the medical instruments supplier’s stock valued at $10,371,000 after buying an additional 16,537 shares in the last quarter. Van ECK Associates Corp raised its position in shares of Becton, Dickinson and Company by 3.1% in the fourth quarter. Van ECK Associates Corp now owns 14,738 shares of the medical instruments supplier’s stock valued at $3,344,000 after buying an additional 450 shares in the last quarter. Finally, Asset Management One Co. Ltd. raised its position in shares of Becton, Dickinson and Company by 4.8% in the fourth quarter. Asset Management One Co. Ltd. now owns 135,558 shares of the medical instruments supplier’s stock valued at $30,974,000 after buying an additional 6,265 shares in the last quarter. Institutional investors and hedge funds own 86.97% of the company’s stock.

Becton, Dickinson and Company Stock Performance

Shares of NYSE:BDX opened at $172.06 on Friday. The company’s 50 day simple moving average is $183.03 and its 200 day simple moving average is $213.01. The stock has a market capitalization of $49.31 billion, a price-to-earnings ratio of 28.58, a price-to-earnings-growth ratio of 1.63 and a beta of 0.25. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.13 and a quick ratio of 0.63. Becton, Dickinson and Company has a 1 year low of $163.33 and a 1 year high of $251.99.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings data on Thursday, May 1st. The medical instruments supplier reported $3.35 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.28 by $0.07. The business had revenue of $5.27 billion for the quarter, compared to analysts’ expectations of $5.35 billion. Becton, Dickinson and Company had a net margin of 8.47% and a return on equity of 15.74%. The firm’s quarterly revenue was up 4.5% compared to the same quarter last year. During the same period last year, the firm posted $3.17 earnings per share. As a group, research analysts predict that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, June 30th. Stockholders of record on Monday, June 9th will be issued a dividend of $1.04 per share. The ex-dividend date of this dividend is Monday, June 9th. This represents a $4.16 annualized dividend and a dividend yield of 2.42%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 79.39%.

Insider Transactions at Becton, Dickinson and Company

In other news, EVP Richard Byrd sold 459 shares of the company’s stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $230.00, for a total transaction of $105,570.00. Following the completion of the transaction, the executive vice president now directly owns 6,952 shares in the company, valued at approximately $1,598,960. This represents a 6.19% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP David Shan sold 1,166 shares of the business’s stock in a transaction on Monday, June 2nd. The stock was sold at an average price of $171.19, for a total transaction of $199,607.54. Following the completion of the sale, the executive vice president now directly owns 4,575 shares in the company, valued at approximately $783,194.25. This represents a 20.31% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 2,104 shares of company stock worth $399,675. Corporate insiders own 0.36% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the stock. William Blair downgraded shares of Becton, Dickinson and Company from an “outperform” rating to a “market perform” rating in a research report on Thursday, May 1st. The Goldman Sachs Group downgraded shares of Becton, Dickinson and Company from a “buy” rating to a “neutral” rating and set a $192.00 price target for the company. in a research report on Friday, May 2nd. Stifel Nicolaus dropped their price target on shares of Becton, Dickinson and Company from $280.00 to $224.00 and set a “buy” rating for the company in a research report on Friday, May 2nd. Bank of America downgraded shares of Becton, Dickinson and Company from a “buy” rating to a “neutral” rating and set a $190.00 price target for the company. in a research report on Thursday, May 1st. Finally, Barclays dropped their price target on shares of Becton, Dickinson and Company from $261.00 to $241.00 and set an “overweight” rating for the company in a research report on Tuesday, June 3rd. Eight equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, Becton, Dickinson and Company currently has a consensus rating of “Hold” and a consensus price target of $219.22.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.